Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Effect of exenatide and placebo on biomarkers related to bone metabolism and on bone mineral density. Blood marker | Exenatide (n = 20) Mean ± SD [Range] | Placebo (n = 20) Mean ± SD [Range] | Time p-value | Group p-value | Time x Group p-value (No covariance) | Time x Group p-value (Prolactin covariance): Vitamin D (nmol/L) Baseline End of trial | 62.9 ± 33.8 [8.0 to 126.0] 69.0 ± 37.7 [16.2 to 135.0] | 70.4 ± 33.6 [14.2 to 130.0] 72.8 ± 31.3 [17.0 to 136.0] | 0.14 | 0.59 | 0.51 | 0.67

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder.

Source: Abstract.

Patients were randomized to either receive injections of 2 mg exenatide once-weekly (Bydureon®, AstraZeneca AB, Södertälje, Sweden) or placebo.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Study design awaiting verification · Frontiers in Psychiatry · 2019

Original publication title

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Robert Eriksson; Brian V. Broberg; Pelle L. Ishøy; Nikolaj Bak; Ulrik B. Andersen; Niklas R. Jørgensen; Filip K. Knop; Bjørn H. Ebdrup

Copyright © 2019 Eriksson, Broberg, Ishøy, Bak, Andersen, Jørgensen, Knop and Ebdrup.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusions:

Sex: and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover.

Source: Background:

Abstract: What methods does the paper describe?

In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder. Baseline BTMs were compared to sex: and age-adjusted reference values from a Danish population cohort, and T- and Z-scores were calculated for BMD.

Source: Methods:

Abstract: Results

In women (n = 24), all baseline BTM measurements of procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14% displayed lower CTX. One patient displayed BMD Z-score < −2, and 23% of patients (17% of women and 29% of men) displayed −2.5 < T-scores <: 1 indicating osteopenia, but none had osteoporosis. After treatment, PINP decreased at trend level significance (P = 0.05), and body mass index BMD increased for L2: L4 (P = 0.016). No changes in bone markers were significant after correction for mean prolactin levels.

Source: Results:

Abstract: Conclusions

Sex: and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.

Source: Conclusions:
Authors’ abstract

Background:

Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover.

Methods:

In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder. Baseline BTMs were compared to sex: and age-adjusted reference values from a Danish population cohort, and T- and Z-scores were calculated for BMD.

Results:

In women (n = 24), all baseline BTM measurements of procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14% displayed lower CTX. One patient displayed BMD Z-score < −2, and 23% of patients (17% of women and 29% of men) displayed −2.5 < T-scores <: 1 indicating osteopenia, but none had osteoporosis. After treatment, PINP decreased at trend level significance (P = 0.05), and body mass index BMD increased for L2: L4 (P = 0.016). No changes in bone markers were significant after correction for mean prolactin levels.

Conclusions:

Sex: and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.

Publication and source details

Original title: Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Robert Eriksson; Brian V. Broberg; Pelle L. Ishøy; Nikolaj Bak; Ulrik B. Andersen; Niklas R. Jørgensen; Filip K. Knop; Bjørn H. Ebdrup

Frontiers in Psychiatry · 2019

Edited by: Felice Iasevoli, University of Naples Federico II, Italy

Reviewed by: Domenico De Berardis, Azienda Usl Teramo, Italy; Martino Belvederi Murri, Università di Genova, Italy; Takao Ando, Nagasaki University Hospital, Japan

*Correspondence: Bjørn H. Ebdrup bebdrup@cnsr.dk

This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry

Copyright © 2019 Eriksson, Broberg, Ishøy, Bak, Andersen, Jørgensen, Knop and Ebdrup.2019Eriksson, Broberg, Ishøy, Bak, Andersen, Jørgensen, Knop and Ebdruphttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Lundbeckfonden10.13039/501100003554Københavns Universitet10.13039/501100001734

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:47:06.904970+00:00

DOI: 10.3389/fpsyt.2018.00781 · PMC6360839